NCT07748208 — "A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes" trial site landscape

Public-registry site landscape for NCT07748208, “A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes”, a Breast Cancer study sponsored by Hoffmann-La Roche. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07748208 (registry record)
Study title	A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
Official title	A Phase II Prospective, Open-Label Safety Study of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With PIK3CA-Mutated Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer and Type 2 Diabetes
Sponsor	Hoffmann-La Roche
Condition(s)	Breast Cancer; Diabetes Type II
Phase	PHASE2
Listed sites	0

Patient-friendly overview of this study: eichor.com/study/NCT07748208.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07748208 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →